from decreasing of foreign sales revenue  Gross profit margin Q2/2018, the Company and its subsidiaries had the total gross profit of 78 MB decreased from Q2/2017 at 2 MB by 2.5 percent while the gross

slightly decreased by 1.46 million baht or 0.87% compared to 168.47 million baht in Q2/2017. - Share of gain from investments in joint ventures in Q2/2018 amounted 198.09 million baht while there was loss

Company and its subsidiaries had the total gross profit of 89.1 MB decreased from Q3/2017 at 26.8 MB by 43.1 percent while the gross profit margin was 35.7 percent (33.5 percent in Q3/2017). The gross

from investments in joint ventures in Q3/2018 amounted 79.14 million baht while there was loss amounted 15.22 million baht in Q3/2017 due to the continuous transfer in MARQUE Sukhumvit project. As of

, decreased by 6.4% compared to last year. Sales revenues reported at Baht 1,407.1 million, decreased by 6.0% mostly due to slower sales in B2B – ASEAN Region while domestic sales stood at par to last year

by 1.5% YoY due to Kyat currency depreciation (at constant FX, total Myanmar sales would have been +6.8%). Laos grew 7.5% YoY while Cambodia performance was dragged by high stock level with the

Directors of the Company considered and viewed that the hospital business is an interesting business to invest and has been interested in investing in this business for a while. The Board of Directors

independent appraisal firm, rewarded by SEC and service fee was comparable to the market value. There is no sign of transfer benefit between related parties while there was the resolution from the Audit

customers, while maintaining and controlling in product cost position including managing Foreign Exchange more efficiency. Moreover, the Company has operated to get product approval from Brand Owners. In the

public interest. While the nature of an auditor oversight body and the process through which it carries out its activities may differ among jurisdictions, IOSCO believes that effective oversight generally